GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Investments And Advances

Pharmaron Beijing Co (SZSE:300759) Investments And Advances : ¥0 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Investments And Advances?

Pharmaron Beijing Co's Investments And Advances for the quarter that ended in Sep. 2024 was ¥0 Mil.


Pharmaron Beijing Co Investments And Advances Historical Data

The historical data trend for Pharmaron Beijing Co's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Investments And Advances Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharmaron Beijing Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharmaron Beijing Co Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Pharmaron Beijing Co Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Executives
Lou Xiao Qiang Directors, executives
Zheng Bei Directors, executives

Pharmaron Beijing Co Headlines

No Headlines